Literature DB >> 15009832

Efficacy of milnacipran for depressive symptoms in schizophrenia spectrum disorders.

Shinsuke Nakanishi, Hiroshi Kunugi, Toshihiko Takahashi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15009832     DOI： 10.1111/j.1440-1819.2003.01222.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN： 1323-1316            Impact factor:   5.188


× No keyword cloud information.
  3 in total

1.  Relationship between Antidepressant Prescription Rates and Features of Schizophrenic Patients and Its Outcome in Schizophrenia Treatment.

Authors:  Nurcan Hanci; Özlem Çetin Eker; Özlem Miraloğlu; Meral Argun Uslu; Güven Özkaya; Salih Saygın Eker
Journal:  Noro Psikiyatr Ars       Date:  2015-03-01       Impact factor: 1.339

2.  Successful Add-on Viloxazine to Clozapine-Responsive Schizophrenia Mitigated Cognitive, Negative and Metabolic Domains.

Authors:  Ahmed Naguy; Reda Rushdy; Saxby Pridmore; Anubhuti Singh; Bibi Alamiri
Journal:  Psychopharmacol Bull       Date:  2022-02-25

3.  Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan.

Authors:  Teruhiko Higuchi; Mike Briley
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.